{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/going-beyond-boundaries-clinical-trial-how-dr-barbara-gillespie-working-address#webpage",
"url": "https://www.fortrea.com/insights/going-beyond-boundaries-clinical-trial-how-dr-barbara-gillespie-working-address",
"name": "Going beyond the boundaries of a clinical trial: how Dr. Barbara Gillespie is working to address disparities in kidney disease",
"description": "Explore how nephrology clinical trials are evolving through data sharing, collaborative research, and the development of meaningful clinical endpoints for kidney diseases. Learn how endpoint development in nephrology, including proteinuria and GFR-based measures, supports regulatory pathways and accelerates drug development for conditions such as focal segmental glomerulosclerosis (FSGS). Explore how collaboration across registries, academia, and industry enables more efficient trial design, faster enrollment, and improved study execution in rare kidney diseases. Learn how integrating real-world data and shared insights helps address unmet needs, reduce development timelines, and improve outcomes for patients with chronic and rare renal conditions. By advancing endpoint strategies and collaborative models, nephrology clinical trials can deliver more effective and timely therapeutic innovations."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Going beyond the boundaries of a clinical trial: how Dr. Barbara Gillespie is working to address disparities in kidney disease",
"item": "https://www.fortrea.com/insights/going-beyond-boundaries-clinical-trial-how-dr-barbara-gillespie-working-address"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/going-beyond-boundaries-clinical-trial-how-dr-barbara-gillespie-working-address#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/going-beyond-boundaries-clinical-trial-how-dr-barbara-gillespie-working-address#webpage"
},
"headline": "Nephrology Clinical Trials and Kidney Disease Endpoint Development Strategies | Fortrea Insights",
"description": "Explore how nephrology clinical trials are evolving through data sharing, collaborative research, and the development of meaningful clinical endpoints for kidney diseases. Learn how endpoint development in nephrology, including proteinuria and GFR-based measures, supports regulatory pathways and accelerates drug development for conditions such as focal segmental glomerulosclerosis (FSGS). Explore how collaboration across registries, academia, and industry enables more efficient trial design, faster enrollment, and improved study execution in rare kidney diseases. Learn how integrating real-world data and shared insights helps address unmet needs, reduce development timelines, and improve outcomes for patients with chronic and rare renal conditions. By advancing endpoint strategies and collaborative models, nephrology clinical trials can deliver more effective and timely therapeutic innovations.",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-11-14",
"dateModified": "2024-11-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-11/AR_0010_Nephrology.pdf",
"encodingFormat": "application/pdf"
}
}
]
}